WallStSmart

Janus Living, Inc. (JAN)vsWelltower Inc (WELL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Welltower Inc generates 1665% more annual revenue ($12.76B vs $723.01M). WELL leads profitability with a 12.1% profit margin vs 1.8%. WELL earns a higher WallStSmart Score of 57/100 (C).

JAN

Avoid

35

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.0Quality: 6.3
Piotroski: 4/9Altman Z: 1.64

WELL

Buy

57

out of 100

Grade: C

Growth: 10.0Profit: 5.5Value: 2.0Quality: 5.0
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JAN.

WELLSignificantly Overvalued (-87.0%)

Margin of Safety

-87.0%

Fair Value

$125.97

Current Price

$235.62

$109.65 premium

UndervaluedFair: $125.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JAN2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
45.4%10/10

Revenue surging 45.4% year-over-year

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

WELL3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
39.1%10/10

Revenue surging 39.1% year-over-year

Market CapQuality
$169.78B9/10

Large-cap with strong market position

EPS GrowthGrowth
35.6%8/10

Earnings expanding 35.6% YoY

Areas to Watch

JAN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.644/10

Distress zone — elevated risk

Profit MarginProfitability
1.8%3/10

1.8% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

WELL4 concerns · Avg: 2.3/10
Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

PEG RatioValuation
3.622/10

Expensive relative to growth rate

P/E RatioValuation
105.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : JAN

The strongest argument for JAN centers on Revenue Growth, Price/Book. Revenue growth of 45.4% demonstrates continued momentum.

Bull Case : WELL

The strongest argument for WELL centers on Revenue Growth, Market Cap, EPS Growth. Revenue growth of 39.1% demonstrates continued momentum.

Bear Case : JAN

The primary concerns for JAN are EPS Growth, Altman Z-Score, Profit Margin. Thin 1.8% margins leave little buffer for downturns.

Bear Case : WELL

The primary concerns for WELL are Return on Equity, PEG Ratio, P/E Ratio. A P/E of 105.2x leaves little room for execution misses.

Key Dynamics to Monitor

JAN profiles as a hypergrowth stock while WELL is a growth play — different risk/reward profiles.

JAN is growing revenue faster at 45.4% — sustainability is the question.

WELL generates stronger free cash flow (881M), providing more financial flexibility.

Monitor REIT - RESIDENTIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WELL scores higher overall (57/100 vs 35/100) and 39.1% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Janus Living, Inc.

REAL ESTATE · REIT - RESIDENTIAL · USA

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.

Welltower Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure.

Visit Website →

Want to dig deeper into these stocks?